Accord Healthcare intros generic Aubagio
Accord Healthcare is offering teriflunomide, which is the generic of Sanofi Genzyme's Aubagio. It is indicated for treating relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease in adults.
Accord's generic product is available in a 14 mg tablet and a 7 mg tablet and is currently available to ship.
The FDA approves Teriflunomide as an immunomodulatory agent in patients 18 and older to decrease the frequency and severity of disease flare-ups—called relapses—to prevent new symptoms or a worsening of old symptoms related to the disease's neurologic impact.
[Read more: Novartis gets FDA OK on new indication for Kesimpta]
"We're proud to add teriflunomide to our portfolio. This is an important oral therapy for the millions of patients living with relapsing MS," said Jim Brown, Accord Healthcare U.S. vice president of sales. "Generic medicine allows broad access to effective therapy, to help improve disease course and potentially slow progression of MS."
Teriflunomide belongs to a class of drugs known as immunomodulatory agents or disease-modifying therapy. It works by inhibiting an enzyme essential to a biochemical pathway involved in the proliferation of lymphocytes, a type of white blood cell. Fewer activated lymphocytes reduce inflammation and immune reactivity to reduce relapse rates and to protect against brain volume loss resulting from inflammatory attacks on the nerve cells in the brain.
The FDA first approved Teriflunomide in 2012.
[Read more: Accord Healthcare offers generic Latuda